Evaxion Biotech AS Net Income
| EVAX Stock | USD 3.40 0.07 2.02% |
As of the 11th of February 2026, Evaxion Biotech shows the Standard Deviation of 6.13, coefficient of variation of (1,047), and Mean Deviation of 4.59. Evaxion Biotech AS technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Evaxion Biotech Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.3413 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -9.5 M | -10 M | |
| Net Loss | -22.1 M | -23.2 M | |
| Net Loss | -9.5 M | -10 M | |
| Net Loss | (11.33) | (11.89) | |
| Net Income Per E B T | 0.84 | 0.75 |
Evaxion | Net Income | Build AI portfolio with Evaxion Stock |
The evolution of Net Income for Evaxion Biotech AS provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Evaxion Biotech compares to historical norms and industry peers.
Latest Evaxion Biotech's Net Income Growth Pattern
Below is the plot of the Net Income of Evaxion Biotech AS over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Evaxion Biotech AS financial statement analysis. It represents the amount of money remaining after all of Evaxion Biotech AS operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Evaxion Biotech's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evaxion Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (10.57 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Evaxion Net Income Regression Statistics
| Arithmetic Mean | (10,347,936) | |
| Coefficient Of Variation | (65.55) | |
| Mean Deviation | 5,237,198 | |
| Median | (5,535,000) | |
| Standard Deviation | 6,783,020 | |
| Sample Variance | 46T | |
| Range | 19M | |
| R-Value | (0.60) | |
| Mean Square Error | 31.4T | |
| R-Squared | 0.36 | |
| Significance | 0.01 | |
| Slope | (805,702) | |
| Total Sum of Squares | 736.1T |
Evaxion Net Income History
Other Fundumenentals of Evaxion Biotech AS
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Evaxion Biotech Net Income component correlations
Evaxion Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Evaxion Biotech is extremely important. It helps to project a fair market value of Evaxion Stock properly, considering its historical fundamentals such as Net Income. Since Evaxion Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Evaxion Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Evaxion Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evaxion Biotech. Projected growth potential of Evaxion fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Evaxion Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.00) | Revenue Per Share | Quarterly Revenue Growth 1.483 | Return On Assets | Return On Equity |
The market value of Evaxion Biotech AS is measured differently than its book value, which is the value of Evaxion that is recorded on the company's balance sheet. Investors also form their own opinion of Evaxion Biotech's value that differs from its market value or its book value, called intrinsic value, which is Evaxion Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evaxion Biotech's market value can be influenced by many factors that don't directly affect Evaxion Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Evaxion Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evaxion Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Evaxion Biotech's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Evaxion Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Evaxion Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Evaxion Biotech.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Evaxion Biotech on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Evaxion Biotech AS or generate 0.0% return on investment in Evaxion Biotech over 90 days. Evaxion Biotech is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. Evaxion Biotech AS, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherap... More
Evaxion Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Evaxion Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Evaxion Biotech AS upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 37.88 | |||
| Value At Risk | (8.42) | |||
| Potential Upside | 9.43 |
Evaxion Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evaxion Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Evaxion Biotech's standard deviation. In reality, there are many statistical measures that can use Evaxion Biotech historical prices to predict the future Evaxion Biotech's volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (1.23) | |||
| Treynor Ratio | (1.73) |
Evaxion Biotech February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (1.72) | |||
| Mean Deviation | 4.59 | |||
| Coefficient Of Variation | (1,047) | |||
| Standard Deviation | 6.13 | |||
| Variance | 37.57 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (1.23) | |||
| Treynor Ratio | (1.73) | |||
| Maximum Drawdown | 37.88 | |||
| Value At Risk | (8.42) | |||
| Potential Upside | 9.43 | |||
| Skewness | 0.4701 | |||
| Kurtosis | 1.86 |
Evaxion Biotech AS Backtested Returns
Evaxion Biotech AS secures Sharpe Ratio (or Efficiency) of -0.11, which denotes the company had a -0.11 % return per unit of standard deviation over the last 3 months. Evaxion Biotech AS exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Evaxion Biotech's Standard Deviation of 6.13, mean deviation of 4.59, and Coefficient Of Variation of (1,047) to check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.34, which means possible diversification benefits within a given portfolio. As returns on the market increase, Evaxion Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Evaxion Biotech is expected to be smaller as well. At this point, Evaxion Biotech AS has a negative expected return of -0.67%. Please make sure to confirm Evaxion Biotech's information ratio, as well as the relationship between the potential upside and rate of daily change , to decide if Evaxion Biotech AS performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.1 |
Very weak reverse predictability
Evaxion Biotech AS has very weak reverse predictability. Overlapping area represents the amount of predictability between Evaxion Biotech time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Evaxion Biotech AS price movement. The serial correlation of -0.1 indicates that less than 10.0% of current Evaxion Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.1 | |
| Spearman Rank Test | 0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 0.6 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Evaxion Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Evaxion Biotech AS reported net income of (10.57 Million). This is 103.1% lower than that of the Biotechnology sector and 115.09% lower than that of the Health Care industry. The net income for all United States stocks is 101.85% higher than that of the company.
Evaxion Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evaxion Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evaxion Biotech could also be used in its relative valuation, which is a method of valuing Evaxion Biotech by comparing valuation metrics of similar companies.Evaxion Biotech is currently under evaluation in net income category among its peers.
Evaxion Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Evaxion Biotech from analyzing Evaxion Biotech's financial statements. These drivers represent accounts that assess Evaxion Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Evaxion Biotech's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 107.7M | 52.4M | 23.4M | 4.5M | 5.2M | 5.0M | |
| Enterprise Value | 79.2M | 49.5M | 28.7M | 9.6M | 11.0M | 10.5M |
Evaxion Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Evaxion Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Evaxion Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Evaxion Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Evaxion Biotech that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Evaxion Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Evaxion Biotech's value.| Shares | Armistice Capital, Llc | 2025-03-31 | 0.0 | Xtx Topco Ltd | 2025-06-30 | 0.0 | Invst Llc | 2025-03-31 | 0.0 | Ikarian Capital, Llc | 2025-06-30 | 80 K | Boothbay Fund Management, Llc | 2025-06-30 | 23.7 K | Rhumbline Advisers | 2025-06-30 | 9.4 K | Gamma Investing Llc | 2025-06-30 | 3.5 K | Ubs Group Ag | 2025-06-30 | 2 K | Beacon Capital Management, Llc | 2025-06-30 | 972 | Sbi Securities Co Ltd | 2025-06-30 | 64.0 | Advisor Group Holdings, Inc. | 2025-06-30 | 25.0 |
Evaxion Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.71) % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | 25.56 M | ||||
| Shares Outstanding | 8.34 M | ||||
| Shares Owned By Insiders | 18.38 % | ||||
| Shares Owned By Institutions | 6.04 % | ||||
| Number Of Shares Shorted | 105.48 K | ||||
| Price To Book | 4.81 X | ||||
| Price To Sales | 3.78 X | ||||
| Revenue | 3.34 M | ||||
| Gross Profit | 7.65 M | ||||
| EBITDA | (9.79 M) | ||||
| Net Income | (10.57 M) | ||||
| Cash And Equivalents | 25.25 M | ||||
| Cash Per Share | 1.06 X | ||||
| Total Debt | 10.1 M | ||||
| Debt To Equity | 0.48 % | ||||
| Current Ratio | 6.47 X | ||||
| Book Value Per Share | 2.61 X | ||||
| Cash Flow From Operations | (12.94 M) | ||||
| Short Ratio | 1.31 X | ||||
| Earnings Per Share | (4.00) X | ||||
| Target Price | 12.33 | ||||
| Number Of Employees | 46 | ||||
| Beta | 0.3 | ||||
| Market Capitalization | 28.94 M | ||||
| Total Asset | 12.48 M | ||||
| Retained Earnings | (118.54 M) | ||||
| Working Capital | 4.4 M | ||||
| Net Asset | 12.48 M |
About Evaxion Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evaxion Biotech AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evaxion Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evaxion Biotech AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.